+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncology Based In-Vivo CRO Market by Animal Model (Murine, Non Murine), Route Of Administration (Intravenous, Oral, Subcutaneous), Therapeutic Modality, End User - Global Forecast 2025-2030- Product Image
Oncology Based In-Vivo CRO Market by Animal Model (Murine, Non Murine), Route Of Administration (Intravenous, Oral, Subcutaneous), Therapeutic Modality, End User - Global Forecast 2025-2030- Product Image
Sale

Oncology Based In-Vivo CRO Market by Animal Model (Murine, Non Murine), Route Of Administration (Intravenous, Oral, Subcutaneous), Therapeutic Modality, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888779
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Oncology Based In-Vivo CRO Market is rapidly evolving as sponsors pursue advanced preclinical solutions to accelerate oncology drug development. As technology adoption, regulatory complexity, and market demands rise, decision-makers require validated, actionable insights to remain competitive and responsive within this sector.

Market Snapshot: Oncology Based In-Vivo CRO Market Growth & Outlook

The Oncology Based In-Vivo CRO Market grew from USD 1.41 billion in 2024 to USD 1.57 billion in 2025. It is expected to continue growing at a CAGR of 11.46%, reaching USD 2.70 billion by 2030. This trajectory reflects increasing demand for sophisticated animal models, integration of advanced imaging techniques, and expanded therapeutic exploration among sponsors and research organizations.

Scope & Segmentation: In-Depth Coverage of In Vivo Oncology Trials

This report delivers a structured analysis across critical market segments and regional dynamics, equipping senior leaders with clarity for strategic planning:

  • Animal Model: Murine, including genetically engineered, immunocompetent syngeneic, and mouse xenograft models; Non-murine hosts such as dog, rabbit, and rat for diverse physiological or immunological requirements.
  • Route of Administration: Intravenous for rapid systemic delivery, oral for clinical mirroring, subcutaneous for sustained-release and biologics.
  • Therapeutic Modality: Chemotherapy, immunotherapy (checkpoint inhibitors, monoclonal antibodies), targeted therapy (kinase inhibitors, small molecule inhibitors).
  • End User: Academia and research institutes, contract research organizations, and pharmaceutical sponsors collaborating to drive preclinical innovation.
  • Regions: Americas—including United States (California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio), Canada, Mexico, Brazil, Argentina; Europe, Middle East & Africa—including the United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland; Asia-Pacific—including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan.
  • Technology Adoption: AI-driven analytics, high-resolution imaging, bioinformatics integration, and collaborative platforms accelerate trial efficiency and data granularity.
  • Key Companies: Charles River Laboratories International, Inc., Laboratory Corporation of America Holdings, WuXi AppTec Co., Ltd., Inotiv, Inc., Crown Bioscience, Inc., Taconic Biosciences, Inc., Pharmaron (Group) Co., Ltd., Explora BioLabs, Inc., GenScript ProBio Co., Ltd., Oncodesign SA.

Key Takeaways: Strategic Insights for Decision-Makers

  • Collaboration between biotechnology firms, CROs, and academic centers is streamlining study execution and promoting reproducibility in oncology research.
  • Integration of data analytics and digital twin methodologies supports robust endpoint analysis, enabling agile trial adaptation.
  • Emergence of novel animal models is enhancing translational accuracy for immunotherapies and targeted agents.
  • Operational excellence in assay design, data validation, and logistics management is increasingly essential to maintain competitive advantage and regulatory compliance.
  • Diversified procurement and supplier partnerships are central strategies for overcoming resource volatility and supply disruptions.
  • Early engagement and scenario-based study governance can reduce risk, minimize amendments, and accelerate timelines from preclinical assessment to trial readiness.

Tariff Impact: Navigating the 2025 U.S. Policy Shift

The 2025 United States tariff policies have prompted CROs and sponsors to adapt sourcing and budgetary approaches. Stakeholders are now diversifying supplier bases, investing in domestic partnerships, and adopting adaptive study protocols to counteract increased import costs and supply chain volatility. This adjustment is fostering enhanced risk management and transparency across the preclinical ecosystem while reinforcing focus on ethical sourcing and supply sustainability.

Methodology & Data Sources

The report synthesizes qualitative insights from in-depth interviews with senior biologists, laboratory directors, and procurement managers, alongside extensive secondary research from peer-reviewed publications and regulatory guidelines. Analytical rigor is upheld through scenario assessment, comparative benchmarking, and multi-vendor data validation protocols.

Why This Report Matters: Enabling Confident Decisions

  • Provides clear segmentation, regional intelligence, and technology trend analysis to guide investment and operational strategies.
  • Equips stakeholders with actionable insights into regulatory shifts, supply dynamics, and collaboration models for competitive positioning.
  • Facilitates risk mitigation and efficiency gains by mapping evolving procurement and study governance frameworks.

Conclusion

Senior decision-makers will benefit from this comprehensive analysis of the Oncology Based In-Vivo CRO Market, gaining both strategic context and practical recommendations for future growth. As innovation and complexity increase, informed, agile approaches will be essential for sustained success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of humanized mouse models for preclinical assessment of immuno-oncology therapies requiring complex T-cell interactions
5.2. Integration of advanced intravital microscopy and PET/MRI imaging to enhance real-time tumor progression and drug distribution studies in in-vivo models
5.3. Adoption of CRISPR/Cas9-engineered tumor models to accelerate target validation and functional genomics in oncology in-vivo research
5.4. Implementation of patient-derived xenograft (PDX) models reflecting diverse tumor heterogeneity for personalized oncology drug testing strategies
5.5. Utilization of high-throughput in-vivo screening platforms to expedite lead compound optimization and reduce time to IND submission
5.6. Expansion of GLP-compliant in-vivo CRO facilities in Asia-Pacific to meet the growing demand for regulatory-grade oncology data
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Oncology Based In-Vivo CRO Market, by Animal Model
8.1. Introduction
8.2. Murine
8.2.1. Genetically Engineered Mouse Model
8.2.2. Immunocompetent Syngeneic
8.2.3. Mouse Xenograft
8.3. Non Murine
8.3.1. Dog
8.3.2. Rabbit
8.3.3. Rat
9. Oncology Based In-Vivo CRO Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Oncology Based In-Vivo CRO Market, by Therapeutic Modality
10.1. Introduction
10.2. Chemotherapy
10.3. Immunotherapy
10.3.1. Checkpoint Inhibitors
10.3.2. Monoclonal Antibodies
10.4. Targeted Therapy
10.4.1. Kinase Inhibitors
10.4.2. Small Molecule Inhibitors
11. Oncology Based In-Vivo CRO Market, by End User
11.1. Introduction
11.2. Academia & Research Institute
11.3. Contract Research Organization
11.4. Pharmaceutical
12. Americas Oncology Based In-Vivo CRO Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Oncology Based In-Vivo CRO Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Oncology Based In-Vivo CRO Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Charles River Laboratories International, Inc.
15.3.2. Laboratory Corporation of America Holdings
15.3.3. WuXi AppTec Co., Ltd.
15.3.4. Inotiv, Inc.
15.3.5. Crown Bioscience, Inc.
15.3.6. Taconic Biosciences, Inc.
15.3.7. Pharmaron (Group) Co., Ltd.
15.3.8. Explora BioLabs, Inc.
15.3.9. GenScript ProBio Co., Ltd.
15.3.10. Oncodesign SA
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ONCOLOGY BASED IN-VIVO CRO MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ONCOLOGY BASED IN-VIVO CRO MARKET: RESEARCHAI
FIGURE 24. ONCOLOGY BASED IN-VIVO CRO MARKET: RESEARCHSTATISTICS
FIGURE 25. ONCOLOGY BASED IN-VIVO CRO MARKET: RESEARCHCONTACTS
FIGURE 26. ONCOLOGY BASED IN-VIVO CRO MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ONCOLOGY BASED IN-VIVO CRO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 104. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 105. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 106. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 107. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 108. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 109. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 112. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 113. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 114. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 115. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 116. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 117. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 120. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 121. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 122. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 123. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 124. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 125. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 128. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 129. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 130. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 131. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 132. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 133. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 202. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 203. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 204. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 205. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 206. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 207. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 210. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 211. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 212. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 213. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 214. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 215. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 218. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 219. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 220. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 221. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 222. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 223. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 226. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 227. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 228. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 229. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 230. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 231. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 250. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 251. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 252. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 253. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 254. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 255. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 258. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 259. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 260. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 261. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 262. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 263. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 266. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 267. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 268. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 269. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 270. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 271. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 274. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 275. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 276. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 277. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 278. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 279. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2024 (USD MILLION)
TABLE 31

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Oncology Based In-Vivo CRO market report include:
  • Charles River Laboratories International, Inc.
  • Laboratory Corporation of America Holdings
  • WuXi AppTec Co., Ltd.
  • Inotiv, Inc.
  • Crown Bioscience, Inc.
  • Taconic Biosciences, Inc.
  • Pharmaron (Group) Co., Ltd.
  • Explora BioLabs, Inc.
  • GenScript ProBio Co., Ltd.
  • Oncodesign SA

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.57 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.7 Billion
Compound Annual Growth Rate11.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

In Vivo CRO Market by Type (Non-Rodent, Rodent), Service Type (Clinical Services, Consulting & Strategy, Laboratory Services), Modality, Indication, End User - Global Forecast 2025-2030 - Product Image

In Vivo CRO Market by Type (Non-Rodent, Rodent), Service Type (Clinical Services, Consulting & Strategy, Laboratory Services), Modality, Indication, End User - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Oncology Based in-Vivo CRO Market Report by Indication, Model, Application, and Region 2025-2033 - Product Image

Oncology Based in-Vivo CRO Market Report by Indication, Model, Application, and Region 2025-2033

  • Report
  • 148 Pages
  • Global
From
Oncology Based In-Vivo CRO Market Report and Forecast 2025-2034 - Product Image

Oncology Based In-Vivo CRO Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Oncology Based In-Vivo CRO - Global Strategic Business Report - Product Image

Oncology Based In-Vivo CRO - Global Strategic Business Report

  • Report
  • 129 Pages
  • Global
From
In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type, By Modality, By Indication, By GLP Type, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type, By Modality, By Indication, By GLP Type, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From

About the Oncology Based In Vivo CRO Market

The Oncology Based In Vivo CRO market is a subset of the biotechnology industry that focuses on providing preclinical services for oncology drug development. These services include animal models, pharmacology, toxicology, and imaging studies. The goal of these services is to provide data that can be used to support the safety and efficacy of oncology drugs. The market is driven by the increasing demand for new treatments for cancer, as well as the need for more efficient and cost-effective drug development. The Oncology Based In Vivo CRO market is highly competitive, with a number of companies offering services in this area. Some of the major players in the market include Charles River Laboratories, Covance, WIL Research, and Envigo. Other companies in the market include MPI Research, SRI International, and Taconic Biosciences. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.